Clinical Trials on Chronic Hepatitis C in Belgium

Total 1372 results

Atea Pharmaceuticals, Inc.

Withdrawn

Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects

Hepatitis C Virus Infection | Hepatitis C | Hepatitis C, Chronic | Chronic Hepatitis C | HCV Infection

Belgium
Erasme University Hospital

Completed

sgp130 in Chronic Human Liver Disease

Chronic Hepatitis C Virus Infection | Alcoholic Liver Disease

Belgium
Atea Pharmaceuticals, Inc.

Completed

Study of AT-527 in Healthy and HCV-Infected Subjects

Hepatitis C | Hepatitis C, Chronic | Chronic Hepatitis C

Belgium, Moldova, Republic of
Erasme University Hospital

Completed

Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease

Alcoholic Liver Disease | Chronic Hepatitis C Virus

Belgium
Atea Pharmaceuticals, Inc.

Completed

Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection

Hepatitis C Virus Infection | Hepatitis C | Hepatitis C, Chronic | Chronic Hepatitis C | HCV Infection

Belgium, Mauritius, Moldova, Republic of
Janssen R&D Ireland

Completed

A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus

Chronic Hepatitis C

Belgium, Germany
Cliniques universitaires Saint-Luc- Université...

Unknown

Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis C

Hepatitis C, Chronic

Belgium
Janssen R&D Ireland

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients (RESTORE)

Hepatitis C

France, Belgium
Centre Hospitalier Universitaire Saint Pierre
AbbVie; Gilead Sciences; Cepheid; Réseau Hépatite C Bruxelles

Completed

HCV RNA Fingerstick Assay as Useful Point of Care of Diagnostic Tool for Drug Users in Brussels

Hepatitis C, Chronic

Belgium
Janssen Sciences Ireland UC

Completed

A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

Hepatitis C, Chronic

Belgium
Novartis Pharmaceuticals

Completed

Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

Chronic Hepatitis C Genotype-1 Relapse

Belgium, United States, Germany, Spain, Puerto Rico, Taiwan, Australia
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation (REPLACE)

Chronic Hepatitis C Virus (HCV) Infection

France, United Kingdom, Spain, Germany, Belgium, Austria
AbbVie

Completed

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects (ZIRCON)

Chronic Hepatitis C Infection

United States, Belgium, Germany, Puerto Rico, Spain
Tibotec BVBA

Completed

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Chronic Hepatitis C

France, Spain, Belgium, Germany, Austria, Netherlands
Janssen Pharmaceutica N.V., Belgium

Completed

Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C (INTEGRATE)

Hepatitis, Chronic

France, United Kingdom, Belgium, Germany, Netherlands, Switzerland
AbbVie

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection (DORA)

Hepatitis C Virus (HCV)

United States, Belgium, Canada, Germany, Japan, Puerto Rico, Russian Federation, Spain, United Kingdom
Debiopharm International SA
Parexel

Completed

A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients

Chronic Hepatitis C

Spain, Belgium, Germany, Romania, France, Poland, Italy
AbbVie

Completed

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection (ENDURANCE-5 6)

Hepatitis C Virus (HCV)

United States, Australia, Belgium, Canada, France, New Zealand, Singapore, South Africa, Vietnam
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Chronic Hepatitis C Infection

United States, Spain, United Kingdom, Canada, Germany, France, Austria, Poland, Belgium, Czech Republic, Italy
Bristol-Myers Squibb

Terminated

Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV (DIMENSION)

Chronic Hepatitis C Infection

France, Germany, United States, Spain, Canada, Argentina, Mexico, Belgium, Italy, Russian Federation, United Kingdom, Poland
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Genotype 1 Chronic Hepatitis C | Treatment Naive

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Spain, Sweden, Brazil, Austria, Ireland, Mexico
Atea Pharmaceuticals, Inc.

Recruiting

A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

Hepatitis C | Hepatitis C, Chronic | HCV | Chronic Hepatitis C Virus | Hepatic Cirrhosis

Turkey, Brazil, Romania, Canada, Philippines, Pakistan, South Africa, Moldova, Republic of, India, Korea, Republic of, Mauritius
Hoffmann-La Roche

Terminated

A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6

Hepatitis C, Chronic

Belgium
Human Genome Sciences Inc.
Novartis

Completed

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

Chronic Hepatitis C

Korea, Republic of, United States, Spain, Canada, France, Australia, Israel, Singapore, Thailand, Malaysia, Sweden, Belgium, Germany, Taiwan, Poland, Argentina, India, Puerto Rico, Brazil, Mexico, United Kingdom
Gilead Sciences

Terminated

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Hepatitis C Virus Infection

United States, United Kingdom, Australia, Germany, Italy, New Zealand, Belgium, Poland, Russian Federation
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
AbbVie

Completed

Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6

Hepatitis C

Austria, Belgium, France, Greece, Israel, Italy, Poland, Portugal, Switzerland
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial

Hepatitis C

Argentina, Australia, Belgium, France, Germany, Italy, United States, Canada, Spain, Mexico, Austria, Poland, Netherlands, Korea, Republic of, Puerto Rico, New Zealand, Finland, Greece, Romania
Janssen-Cilag International NV

No longer available

Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C

Australia, Belgium, Germany, Spain, Switzerland, Romania, Serbia, Greece, New Zealand, Brazil, Russian Federation, Austria, Hungary, Czech Republic, Luxembourg
Kirby Institute
Merck Sharp & Dohme LLC

Completed

A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3 (ACTIVATE)

Hepatitis C, Chronic

Australia, Canada, United Kingdom, Belgium, Germany, Norway, Switzerland
Tibotec Pharmaceuticals, Ireland

Completed

A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection

Hepatitis C, Chronic

France, United Kingdom, Belgium, Germany, Poland, Netherlands
Janssen-Cilag International NV

Completed

A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants (COMMIT)

Hepatitis C, Chronic

France, United Kingdom, Belgium, Spain, Germany, Hungary
Janssen Research & Development, LLC

Completed

Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection

Hepatitis C, Chronic

Poland, Belgium, Germany, Spain, Canada, Singapore
Janssen-Cilag International NV

Completed

A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection

Hepatitis C, Chronic | Infection

United Kingdom, Germany, Spain, Belgium, Saudi Arabia, Austria, France
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)

Hepatitis C Virus

Belgium
Tibotec Pharmaceuticals, Ireland

Completed

A Study in Healthy Female Participants Investigating the Effect of TMC435 on the Pharmacokinetics of the Synthetic Hormones of the Oral Contraceptive Ovysmen

Hepatitis C Virus

Belgium
Universitair Ziekenhuis Brussel

Recruiting

Relinking Diagnosed But Untreated HCV Patients Back Into Care. (Relink)

Hepatitis C Virus Infection

Belgium
Tibotec Pharmaceuticals, Ireland

Completed

A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus

Hepatitis C Virus

Belgium
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Hepatitis C, Chronic

United States, Australia, United Kingdom, Germany, France, Spain, Belgium, Netherlands, Canada, Brazil, Puerto Rico, Poland, Sweden, Switzerland, Israel
GlaxoSmithKline
PPD

Completed

Dose Ranging of GSK2336805 in Combination Therapy (HAI115879)

Hepatitis C, Chronic

Puerto Rico, United States, Bulgaria, Germany, Belgium, France
Janssen-Cilag International NV

Completed

Telaprevir Open-Label Study in Co-Infected Patients

Hepatitis C, Chronic

United Kingdom, Belgium, Germany, Portugal, Russian Federation, Hungary, Ireland, Luxembourg
Pfizer

Completed

Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State

Hepatitis C Virus

Belgium
Novartis Pharmaceuticals

Terminated

3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study

Hepatitis C, Chronic

Romania, Italy, Germany, Belgium, Spain, Australia, Thailand, United States, Hungary, Taiwan, Poland, Canada, Puerto Rico, Vietnam, Korea, Republic of, India
Hoffmann-La Roche

Completed

PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Hepatitis C, Chronic

Belgium, Ireland, Italy, United Kingdom
Tibotec BVBA
Tibotec Pharmaceutical Limited

Completed

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Hepatitis C, Chronic

United States, Australia, France, United Kingdom, Germany, Spain, Belgium, Israel, Canada, Brazil, Austria, Poland, Netherlands, Sweden, Switzerland, Puerto Rico
Boehringer Ingelheim

Completed

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Hepatitis C, Chronic

United States, Australia, Belgium, Canada, France, Germany, Greece, Italy, New Zealand, Portugal, Spain, United Kingdom
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Hepatitis C, Chronic

United States, Austria, Belgium, Canada, France, Germany, Japan, Portugal, Puerto Rico, Spain, Switzerland, United Kingdom
Hoffmann-La Roche

Completed

REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy

Hepatitis C, Chronic

Belgium, France, Germany, Italy, Spain, Sweden, United States, Greece, Portugal, Turkey, Switzerland, Canada, United Kingdom, Brazil
Hoffmann-La Roche

Completed

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Hepatitis C, Chronic

Belgium, United States, Germany, Canada, Austria, Switzerland, Puerto Rico, Australia, Brazil, Mexico

Clinical Trials on Chronic Hepatitis C in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations